Skip to main content
Clinical Trials/DRKS00030773
DRKS00030773
Not yet recruiting
未知

patientorientend.graduated.interdisciplinary.network-treatment - PAIN2.0

Deutsche Schmerzgesellschaft e.V.0 sites1,350 target enrollmentNovember 21, 2022

Overview

Phase
未知
Intervention
Not specified
Conditions
recurrent pain episodes with risk for chronification
Sponsor
Deutsche Schmerzgesellschaft e.V.
Enrollment
1350
Status
Not yet recruiting
Last Updated
last year

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
November 21, 2022
End Date
TBD
Last Updated
last year
Study Type
Interventional
Sex
All

Investigators

Sponsor
Deutsche Schmerzgesellschaft e.V.

Eligibility Criteria

Inclusion Criteria

  • (at least 6 weeks ago) newly occurring pain or pain that has occurred repeatedly or persisted for a longer period of time
  • \- pain\-related restrictions relevant to the person affected (possibly already occurring AU, impairment in everyday life/family/leisure time and (home) work), as well as associated deterioration in the quality of life
  • \- a risk of chronification (e.g. spreading pain, stress factors in family and work, pronounced sparing and avoidance behavior):
  • \- Participants in the study are at least 18 years of age, have sufficient knowledge of written and spoken German, live within reach of the participating facility, and have given verbal and written consent to participate in advance.
  • \- Participants are insured with a GKV health insurance company.

Exclusion Criteria

  • Primary exclusion criteria are clinical indications of a serious illness requiring urgent acute therapy red flags, or other acutely effective serious illnesses that prevent activating treatment (e.g. severe heart failure, tumor); a manifest chronic pain illness that has already occurred (e.g. AU due to pain for longer than 6 months, previous IMST in the last two years). (e.g., sick leave due to pain for more than 6 months, previous therapy with strong opioids lasting more than 6 months, previous IMST in the last two years); a severe and active psychiatric disorder (personality disorder, severe depression, indications of suicidal tendencies); an ongoing pension procedure or rehabilitation procedure planned in the near future; linguistic and/or cognitive impairments; ongoing diagnostics and/or therapy with regard to pain\-specific pathology (in these cases, the result should first be awaited). Patients undergoing treatment under the terms of the employers' liability insurance association and with private health insurance are to be excluded.

Outcomes

Primary Outcomes

Not specified

Similar Trials

Completed
Phase 4
patient oriented.graduated.interdisciplinary.network - PAIN2020pain and risk for chronicity
DRKS00015443Deutsche Schmerzgesellschaft e.V. (Konsortialführung)1,223
Recruiting
Not Applicable
Interdisciplinary patient-centred care with quality control within palliative therapy of colorectal carcinoma (IVOPAK II) A Treatment path based on the Guidelines- Personalized therapy of colorectal cancer (CRC) with region-wide controll supplyMetastatic Colorectal CancerC18Malignant neoplasm of colon
DRKS00011856niversitätsklinikum Erlangen250
Completed
Not Applicable
ENHANCED RECOVERY IN HEAD AND NECK CANCER SURGERYHealth Condition 1: C148- Malignant neoplasm of overlappingsites of lip, oral cavity and pharynx
CTRI/2019/07/020352no
Recruiting
Not Applicable
Personalized, interdisziplinary patient pathway to cross-sector care of multimorbid patientsI50J44N18E11E10I70.29I25I10Heart failureOther chronic obstructive pulmonary diseaseChronic kidney diseaseType 2 diabetes mellitusType 1 diabetes mellitusChronic ischaemic heart diseaseEssential (primary) hypertension
DRKS00031500niversität zu Köln946
Not yet recruiting
Not Applicable
OBJECTIVE, CLINICIAN- AND PATIENT-REPORTED EVALUATION OF LATE TOXICITY FOLLOWING ADJUVANT RADIATION IN EARLY BREAST CANCER: FOLLOW-UP RESULTS OF A RANDOMISED SERIESC50L90.5L81.9Malignant neoplasm of breastScar conditions and fibrosis of skinDisorder of pigmentation, unspecified
DRKS00029665Klinik für Strahlentherapie und Radioonkologie; Universitätsklinikum Bonn100